Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Photodynamic therapy update.

M F Shuler1, J L Borrillo, A C Ho

  • 1Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

Current Opinion in Ophthalmology
|June 5, 2001
PubMed
Summary

Photodynamic therapy with verteporfin is approved for age-related macular degeneration causing choroidal neovascularization. This treatment halts visual loss progression in specific patient cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of progressive compression of the aortic true lumen with intraoperative transesophageal echocardiography during repair of dissection of thoracic aorta--a case report.

Acta anaesthesiologica Sinica·2002
Same author

The role of imaging in the diagnosis and management of osteoid osteoma: a pictorial review.

Critical reviews in diagnostic imaging·2002
Same author

Patient-initiated second medical opinions: their necessity and economic cost.

Retina (Philadelphia, Pa.)·2002
Same author

The intubating laryngeal mask airway in severe ankylosing spondylitis.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2001
Same author

Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Treatment of subretinal hemorrhages with tissue plasminogen activator.

Current opinion in ophthalmology·2001

Area of Science:

  • Ophthalmology
  • Medical Therapy
  • Biomedical Engineering

Background:

  • Choroidal neovascularization (CNV) is a leading cause of vision loss.
  • Photodynamic therapy (PDT) utilizes photoactivating agents for targeted treatment.
  • Verteporfin PDT gained FDA approval in April 2000 for specific CNV cases.

Purpose of the Study:

  • To review the application of verteporfin photodynamic therapy.
  • To assess the efficacy of PDT in treating choroidal neovascularization.
  • To explore the potential of other photoactivating agents.

Main Methods:

  • Selective treatment of CNV using a photoactivating agent.
  • FDA approval of verteporfin PDT for subfoveal, predominantly classic CNV in AMD.
  • Ongoing investigation for CNV from other causes and evaluation of alternative agents.

Main Results:

  • Verteporfin PDT is approved for specific types of age-related macular degeneration (AMD) related CNV.
  • The therapy has demonstrated success in halting visual loss progression in eligible AMD patients.
  • Efficacy for CNV from myopia, angioid streaks, and other causes remains under investigation.

Conclusions:

  • Verteporfin PDT is an established treatment for certain forms of AMD-related CNV.
  • Further research is needed to expand PDT applications to other CNV etiologies.
  • The long-term socio-economic impact of verteporfin approval requires further study.

Related Experiment Videos